Workflow
中源协和: 东兴证券股份有限公司关于中源协和细胞基因工程股份有限公司使用闲置募集资金暂时补充流动资金的核查意见
Zheng Quan Zhi Xing·2025-05-21 09:29

Core Viewpoint - The company plans to temporarily use idle raised funds to supplement working capital, which has been approved by the board and supervisory committee, ensuring compliance with relevant regulations [4][5]. Group 1: Fundraising Overview - The company raised a total of 446,999,922.07 RMB through a non-public offering of 27,815,801 shares at a price of 16.07 RMB per share, with a net amount of 444,449,922.07 RMB after deducting related issuance costs [1]. - As of May 15, 2025, the company has a remaining balance of 33,792.44 million RMB in raised funds, with 120 million RMB of idle funds allocated for cash management [2]. Group 2: Temporary Use of Idle Funds - The company intends to use up to 180 million RMB of idle raised funds to temporarily supplement working capital, with a usage period not exceeding 12 months from the board's approval [2]. - The company assures that the use of these funds will not affect the normal progress of the fundraising investment plan and will be related to its main business operations [2]. Group 3: Approval Procedures and Opinions - The proposal to use idle raised funds has been approved by the company's board and supervisory committee in their respective meetings [3]. - The independent financial advisor has confirmed that the proposal complies with relevant regulations and is in the best interest of the company and its shareholders, with no indication of changing the purpose of the raised funds [4][5].